

Tel: 400-999-8863
 ■ Email:Upingbio.163.com



Crk II Polyclonal Antibody

Catalog No YP-Ab-03793 Isotype IgG Reactivity Human;Mouse;Rat;Monkey Applications WB;HC;IF;ELISA Gene Name CRK Protein Name Adapter molecule crk Immunogen The antiserum was produced against synthesized peptide derived from human Crkil. An range:187-236 Specificity Crk II Polyclonal Antibody detects endogenous levels of Crk II protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications. Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm . Cell membrane . Transiocated to the plasma membrane upon cell adhesion . Tissue Specificity Embryonic lung,Epithelium,Eye,Lung,Placen		
Reactivity Human; Mouse; Rat; Monkey Applications WB; HC; IF; ELISA Gene Name CRK Protein Name Adapter molecule crk Immunogen The antiserum was produced against synthesized peptide derived from human Crk II. AA range: 187-236 Specificity Crk II Polyclonal Antibody detects endogenous levels of Crk II protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications. Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm. Cell membrane. Translocated to the plasma membrane upon cell adhesion Tissue Specificity Embryonic lung, Epithelium, Eye, Lung, Placenta, domain: The C-terminal SH3 domain function as a negative modulator for transformation, domain: The SH2 domain mediates interaction with SHB, function: The Crk-II and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-IC. Crk-II mediates attachment-induced MAPK8 activation, membrane urfilling and cell motility via its interaction with DOCK1 and DOCK4. PTM: Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulator of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Catalog No	YP-Ab-03793
Applications WB:IHC;IF;ELISA Gene Name CRK Protein Name Adapter molecule crk Immunogen The antiserum was produced against synthesized peptide derived from human Crkll. AA range:187-236 Specificity Crk II Polyclonal Antibody detects endogenous levels of Crk II protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit,IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution Western Blot: 1/500 - 1/2000. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications. Concentration 1 mg/ml Purity 90% Storage Stability -20°C/1 year Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion . Tissue Specificity Embryonic lung,Epithelium,Eye,Lung,Placenta, domain:The C-terminal SH3 domain appears to function as a positive regulator for transformation and the N-terminal SH3 domain appears to function with SHB, function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-II. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated on Tyr-221 upon cell	Isotype	IgG
Gene Name CRK Protein Name Adapter molecule crk Immunogen The antiserum was produced against synthesized peptide derived from human CrkII. AA range:187-236 Specificity Crk II Polyclonal Antibody detects endogenous levels of Crk II protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution Western Blot: 1/500 - 1/2000. Immunoflistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications. Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion . Tissue Specificity Embryonic lung,Epithelium,Eye,Lung,Placenta, domain:The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a politive regulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation and the N-terminal SH3 domain appears to function with SHB, function:The Crk-I and Crk-II forms differ in their biological activation with SHB, function. The Crk-I crk-I crk-II crk-II mediates attareaction with SHB, function, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DCCK1 and DCCK4, PTM; Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH22 domain. This leads finity to the	Reactivity	Human;Mouse;Rat;Monkey
Immunogen	Applications	WB;IHC;IF;ELISA
Immunogen The antiserum was produced against synthesized peptide derived from human CrkII. AA range:187-236 Specificity Crk II Polyclonal Antibody detects endogenous levels of Crk II protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit,IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications. Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion. Tissue Specificity Embryonic lung, Epithelium, Eye, Lung, Placenta, domain: The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation, domain: The SH2 domain mediates interaction with SHB, function: The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility via its interaction with DOCK1 and DOCK4, PTM: Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Gene Name	CRK
CrkII. AA range:187-236 Specificity Crk II Polyclonal Antibody detects endogenous levels of Crk II protein. Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications. Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion Tissue Specificity Embryonic lung, Epithelium, Eye, Lung, Placenta, domain: The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation., domain: The SH2 domain mediates interaction with SHB., function: The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffing and cell motility a lace-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCKA, PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated of Tyr-221 with the SH2 domain. This leads finally to the	Protein Name	Adapter molecule crk
Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications. Concentration 1 mg/ml Purity 290% Storage Stability -20°C/1 year Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion Tissue Specificity Embryonic lung, Epithelium, Eye, Lung, Placenta, domain: The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation, domain: The SH2 domain mediates interaction with SHB., function: The Crk-I forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility via its interaction with DOCK1 and DOCK4., PTM: Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Immunogen	
Source Polyclonal, Rabbit,IgG Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications. Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm. Cell membrane. Translocated to the plasma membrane upon cell adhesion. Tissue Specificity Embryonic lung, Epithelium, Eye, Lung, Placenta, Function domain: The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation, domain: The SH2 domain mediates interaction with SHB, function: The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4. PTM: Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated from the SH2 domain. This leads f	Specificity	Crk II Polyclonal Antibody detects endogenous levels of Crk II protein.
Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Dilution Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications. Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion . Tissue Specificity Embryonic lung,Epithelium,Eye,Lung,Placenta, domain:The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation. domain: The SH2 domain mediates interaction with SHB, function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4., PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Formulation	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
affinity-chromatography using epitope-specific immunogen. Dilution Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications. Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion Tissue Specificity Embryonic lung,Epithelium,Eye,Lung,Placenta, domain:The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation.,domain:The SH2 domain mediates interaction with SHB.,function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility via its interaction with DOCK1 and DOCK4, PTM.Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Source	Polyclonal, Rabbit,IgG
Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications. Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion Tissue Specificity Embryonic lung,Epithelium,Eye,Lung,Placenta, domain:The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation.,domain:The SH2 domain mediates interaction with SHB.,function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility via its interaction with DOCK1 and DOCK4. PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Purification	, , , , , , , , , , , , , , , , , , , ,
Purity ≥90% Storage Stability -20°C/1 year Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion Tissue Specificity Embryonic lung,Epithelium,Eye,Lung,Placenta, domain:The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformationdomain:The SH2 domain mediates interaction with SHB.,function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPk8 activation, membrane ruffling and cell motility via its interaction with DOCK1 and DOCK4.,PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Dilution	Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other
Storage Stability -20°C/1 year CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion Tissue Specificity Embryonic lung,Epithelium,Eye,Lung,Placenta, domain:The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformationdomain:The SH2 domain mediates interaction with SHB.,function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4.,PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Concentration	1 mg/ml
Synonyms CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 Observed Band 40kD Cell Pathway Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion Tissue Specificity Embryonic lung, Epithelium, Eye, Lung, Placenta, domain: The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation., domain: The SH2 domain mediates interaction with SHB., function: The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4., PTM: Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Purity	≥90%
Observed Band Cell Pathway Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion Tissue Specificity Embryonic lung,Epithelium,Eye,Lung,Placenta, domain:The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation.,domain:The SH2 domain mediates interaction with SHB.,function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4.,PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Storage Stability	-20°C/1 year
Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion Tissue Specificity Embryonic lung, Epithelium, Eye, Lung, Placenta, domain: The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation., domain: The SH2 domain mediates interaction with SHB., function: The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4., PTM: Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Synonyms	CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38
Tissue Specificity Embryonic lung, Epithelium, Eye, Lung, Placenta, domain: The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation., domain: The SH2 domain mediates interaction with SHB., function: The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4., PTM: Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Observed Band	40kD
domain:The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation.,domain:The SH2 domain mediates interaction with SHB.,function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4.,PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Cell Pathway	
transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation.,domain:The SH2 domain mediates interaction with SHB.,function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4.,PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the	Tissue Specificity	Embryonic lung,Epithelium,Eye,Lung,Placenta,
	Function	transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation.,domain:The SH2 domain mediates interaction with SHB.,function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4.,PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the



UpingBio technology Co.,Ltd

📞 Tel: 400-999-8863 🗷 Emall:Upingbio.163.com



Background

This gene encodes a member of an adapter protein family that binds to several tyrosine-phosphorylated proteins. The product of this gene has several SH2 and SH3 domains (src-homology domains) and is involved in several signaling pathways, recruiting cytoplasmic proteins in the vicinity of tyrosine kinase through SH2-phosphotyrosine interaction. The N-terminal SH2 domain of this protein functions as a positive regulator of transformation whereas the C-terminal SH3 domain functions as a negative regulator of transformation. Two alternative transcripts encoding different isoforms with distinct biological activity have been described. [provided by RefSeq, Jul 2008],


matters needing attention

Avoid repeated freezing and thawing!


Usage suggestions

This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.


Products Images



Western Blot analysis of various cells using Crk II Polyclonal Antibody



Immunofluorescence analysis of HUVEC cells, using CrkII Antibody. The picture on the right is blocked with the synthesized peptide.




Immunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue, using CrkII Antibody. The picture on the right is blocked with the synthesized peptide.



UpingBio technology Co.,Ltd

(Tel: 400-999-8863 ■ Emall:Upingbio.163.com





Western blot analysis of lysates from COS7 cells, using CrkII Antibody. The lane on the right is blocked with the synthesized peptide.